oral glp-1 agonist Lesson: Semaglutide: A New Receptor Product for the Treatment of Type 2 Diabetes glp-1_analogs [TUSOM | Pharmwiki]

Back Unger, R, Orci, L (4 Jan 1975) 'The essential role of glucagon in the pathogenesis of diabetes mellitus', The Lancet , 305/7895, 14-16

You can always escalate to tirzepatide later if needed

Researchers are currently trying to pin down the biomarker signatures that indicate if a person will respond well to GLP-1 RAs

In non-obese diabetic (NOD) mice which are a murine model of T1DM, GLP-1RAs can improve immune functions and inflammatory responses as well as mitigating against islet cell damage, an action which may be related to the decrease in the expression of miR-19b [145]

Back Dupr, J (26 Sept 1964) 'An intestinal hormone affecting glucose disposal in man', The Lancet , 672-73

It has multiple actions including: potentiation of glucose-mediated insulin secretion mechanisms identified: increased -cell proliferation, resulting in an increase -cell mass (Fusco et al, 2017) stimulation of insulin biosynthesis at the translational level, helping to maintain -cell insulin stores and secretory capacity (Baggio & Drucker, 2007) because the GLP-1 effect is glucose-dependent (there is more insulin release when glucose levels are elevated, but less effect when glucose levels are normal), GLP-1 agonists have a lower risk for producing hypoglycemia compared to sulfonylureas (that chronically stimulate insulin release, independent of glucose concentration) suppression of postprandial glucagon release Evidence indicates that stimulation of pancreatic cells by GLP-1 increases their glucose sensitivity, resulting in less glucagon release at any glucose level (Baggio & Drucker, 2007)